Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-07
2011-06-07
Young, Shawquia (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S527000
Reexamination Certificate
active
07956084
ABSTRACT:
The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
REFERENCES:
patent: 3963750 (1976-06-01), Goudie
patent: 5258357 (1993-11-01), Muenster et al.
patent: 5571810 (1996-11-01), Matsuo et al.
patent: 5679670 (1997-10-01), Dean et al.
patent: 6048880 (2000-04-01), Kawai et al.
patent: 6380214 (2002-04-01), Gant et al.
patent: 6414013 (2002-07-01), Fancelli et al.
patent: 6699854 (2004-03-01), Wang et al.
patent: 6809088 (2004-10-01), Chabrier de Lassauniere et al.
patent: 6835745 (2004-12-01), Coghlan et al.
patent: 6875790 (2005-04-01), Bertenshaw et al.
patent: 6881735 (2005-04-01), Schindler et al.
patent: 6881741 (2005-04-01), Chan Chun Kong et al.
patent: 7019027 (2006-03-01), Linden et al.
patent: 7084170 (2006-08-01), Grossman et al.
patent: 7084171 (2006-08-01), Grainger et al.
patent: 7125896 (2006-10-01), Faull et al.
patent: 7166639 (2007-01-01), Wan et al.
patent: 7196106 (2007-03-01), Duffy et al.
patent: 2002/0107252 (2002-08-01), Baxter et al.
patent: 2004/0235821 (2004-11-01), Griffiths et al.
patent: 2006/0058522 (2006-03-01), Faull
patent: 2006/0111431 (2006-05-01), Morley et al.
patent: 2007/0015819 (2007-01-01), Faull et al.
patent: 0 202 538 (1986-11-01), None
patent: 0853083 (1998-07-01), None
patent: 0 908 456 (1999-04-01), None
patent: 1468012 (1977-03-01), None
patent: 2195634 (1988-04-01), None
patent: WO 98/02430 (1998-01-01), None
patent: WO 98/54116 (1998-12-01), None
patent: WO 99/46244 (1999-09-01), None
patent: WO 0071532 (2000-11-01), None
patent: WO 01/58890 (2001-08-01), None
patent: WO 0198290 (2001-12-01), None
patent: WO 0230353 (2002-04-01), None
patent: WO 02/46171 (2002-06-01), None
patent: WO 03/010158 (2003-02-01), None
patent: WO 03/010163 (2003-02-01), None
patent: WO 03/028731 (2003-04-01), None
patent: WO 03/029241 (2003-04-01), None
patent: WO 2004/063185 (2004-07-01), None
patent: WO 2004/063186 (2004-07-01), None
Cancer and Metastasis Reviews (1998),17(1), 91-106.
Science (1999), vol. 286, 531-537.
Cancer [online], [retrieved on Jul. 6, 2007] Retrieved from the Intemet, URL; http://www nlm nih gov/medlineplus/cancer html>.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the Intemet, URL; http://en.wikipedia.org/wiki/Cancer>.
Diabetes Guide [online], [retrieved from the internet on Jun. 17, 2008] [URL; http://diabetes.webmd.com/guide/diabetes-overview].
Zayed et al., “Studies on 5-Aminopyrazole Derivatives. Synthesis of Some New Fused Pyrazole Derivatives”,Monatshefie für Chemie115:431-436 (1984).
Awada et al., “The pipeline of new anticancer agents for breast cancer treatment in 2003”,Critical Reviews in Oncology/Hematology48:45-63 (2003).
Berkow et al., The Merck Manual of Diagnosis and Therapy, 16thEdition, © 1992, Merck Research Laboratories, Rahway, NJ, pp. 1488 and 2664.
Chen et al., “TNF-R1 Signaling: A Beautiful Pathway”,Science296:1634-1635 (2002).
Compston et al., “Multiple sclerosis”,The Lancet359:1221-1231 (2002).
Du et al., “Aryl ureas represent a new class of anti-trypanosomal agents”,Chemistry&Biology7:733-742 (2000).
Goluh et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”,Science286:531-537 (1999).
Gripenberg, “Common serological features in rheumatoid arthritis and yersinia arthritis”,Scand. J. Rheumatology10:85-91 (1981).
Hartung et al., “What do we know about the mechanism of action of disease-modifying treatments in MS?”J Neurol251(Suppl. 5):V/12-V/29 (2004).
Karin et al., “NF-κB in cancer: from innocent bystander to major culprit”,Nat. Rev. Cancer2:301-310 (2002).
Lala et al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors”,Cancer and Metastasis Reviews17:91-106 (1998).
Luo et al., “IKK/NF-κB signaling: balancing life and death—a new approach to cancer therapy”,J. Clin. Invest. 115(10):2625-2632 (2005).
Orlowski, et al., “NF-κB as a therapeutic target in cancer”,TRENDS in Molecular Medicine8(8):385-389 (2002).
Parrish et al., “Preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders”, CAPLUS 138:304153, 2003.
Faull Alan
Johnstone Craig
Morley Andrew
Poyser Jeffrey Philip
Astrazeneca AB
Fish & Richardson P.C.
Young Shawquia
LandOfFree
Phenyl thiophene carboxamide compounds as inhibitors of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenyl thiophene carboxamide compounds as inhibitors of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenyl thiophene carboxamide compounds as inhibitors of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2713714